Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 15/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5502868 | 0.86 | BDKRB1 (0.73) | BDKRB1KDM4EALDH1A1LMNAGAA | |
| SCHEMBL4174733 | 0.83 | BDKRB1 (0.69) | BDKRB1KDM4EALDH1A1LMNAGAA | |
| SCHEMBL3535337 | 0.83 | BDKRB1 (0.51) | BDKRB1 | |
| SCHEMBL5506530 | 0.82 | BDKRB1 (0.68) | BDKRB1KDM4EALDH1A1LMNAGAA | |
| SCHEMBL4179697 | 0.80 | BDKRB1 (0.84) | BDKRB1 | |
| SCHEMBL4179702 | 0.80 | BDKRB1 (0.84) | BDKRB1 | |
| SCHEMBL4173172 | 0.79 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL4180236 | 0.79 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL5509025 | 0.79 | BDKRB1 (0.76) | BDKRB1ALDH1A1 | |
| SCHEMBL3535670 | 0.79 | BDKRB1 (0.65) | BDKRB1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817294-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | Amgen Inc. (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006019975-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | AMGEN INC. (US) | 2006-02-23 | — | — | WO | claimed |